Status:
RECRUITING
Phase I Study of ICP-332 in Healthy Subjects
Lead Sponsor:
InnoCare Pharma Inc.
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Eligibility Criteria
Inclusion
- Voluntarily sign the informed consent form
- Body mass index (BMI) of ≥ 18.5 kg/m2 and \< 30 kg/m2
- Male or infertile female subjects who are between 18-55 years old (inclusive)
Exclusion
- Significant current or past acute or chronic disease or condition.
- A history of tuberculosis or current active/latent infection.
- With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
- Subjects with clinically significant abnormalities in the screening examinations.
Key Trial Info
Start Date :
July 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 25 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06530966
Start Date
July 23 2024
End Date
December 25 2024
Last Update
August 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmaron CPC Inc.
Baltimore, Maryland, United States, 21201